Horizon BRAF-Resistant Melanoma PDX Models

Horizon Discovery has launched four new BRAF-resistant melanoma patient derived xenograft (PDX) models. The company has partnered with the Wistar Institute of Anatomy and Biology in Philadelphia to make their melanoma PDX models available to the research community. The models are created by implanting cancerous tissued from a human primary tumor directly into immunodeficient mouse or rat models.They can support drug efficacy studies, the company said.